Theratechnologies has announced that an independent data and safety monitoring board (DSMB) has recommended that its Phase III clinical study on TH9507 for the treatment of HIV associated lipodystrophy be continued as currently being conducted.
"With 280 patients having now completed 13 weeks of treatment, the trial continues to progress on schedule and we expect the first Phase III study results around the end of this year," said Yves Rosconi, the company's president and CEO.
The recommendation made by the DSMB is based on a recent review of the safety data on 181 patients who have been treated for three months. After reviewing the safety data, the DSMB concluded that the trial should continue as per protocol.
